AXNX - Axonics Modulation Technologies, Inc.
| Previous Close | 30.27 |
| Open | 30.68 |
| Bid | 32.31 x 1000 |
| Ask | 32.49 x 900 |
| Day's Range | 29.80 - 33.06 |
| 52 Week Range | 11.95 - 43.37 |
| Volume | 186,525 |
| Avg. Volume | 250,390 |
| Market Cap | 913.792M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.53 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.75 |
- Business Wire
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration (“FDA”). The Axonics System is the first rechargeable SNM system approved for sale in the United States, Europe, Canada and Australia.
- Business Wire
Axonics® to Present at Upcoming Investor Conferences
Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation devi
- GuruFocus.com
Axonics Modulation Technologies Inc (AXNX) CEO Raymond W Cohen Bought $106,435 of Shares
CEO of Axonics Modulation Technologies Inc (30-Year Financial, Insider Trades) Raymond W Cohen (insider trades) bought 3,500 shares of AXNX on 08/06/2019 at an average price of $30.41 a share. Continue reading...
- Business Wire
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation device for the treatment of urinary and bowel dysfunction, reported today financial results for the second quarter ended June 30, 2019, and provided an update on operational initiatives.
- Business Wire
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced completion of 1-year follow-ups and top-line clinical results from its ARTISAN-SNM pivotal clinical study conducted under an U.S. Food & Drug Administration (“FDA”) Investigational Device Exemption (“IDE”) designed to evaluate the safety and efficacy of the Axonics r-SNM® System1. The study results at 1-year demonstrate that patients implanted with the Axonics r-SNM System continue to receive clinically meaningful and statistically significant improvements in urinary urgency incontinence symptoms and quality of life.
- Simply Wall St.
Is Axonics Modulation Technologies (NASDAQ:AXNX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Axonics Modulation Technologies, Inc. (AXNX)
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]
- Business Wire
Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study.
Motley FoolWhy Axonics Modulation Technologies Stock Soared 63% in May
This medical device stock has been on a tear since the company's Halloween 2018 IPO.
- Associated Press
Axonics: 1Q Earnings Snapshot
The Irvine, California-based company said it had a loss of 47 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- Business Wire
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation device for the treatment of urinary and bowel dysfunction, reported today financial results for the first quarter ended March 31, 2019, and provided an update on operational initiatives.
- Business Wire
Axonics® Announces ARTISAN-SNM Pivotal Study Results Presented at the American Urological Association Annual Meeting
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced the presentation of positive results from the ARTISAN-SNM pivotal study, designed to gain market approval from the U.S. Food & Drug Administration (FDA) for the Axonics r-SNM® System1. ARTISAN-SNM study results were presented on May 5 at the 2019 American Urological Association (AUA) Annual Meeting in Chicago by Professor Howard Goldman, M.D., of the Cleveland Clinic.
- Business Wire
Axonics® to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the first quarter of 2019 and provide an update on operations and FDA regulatory status after the market closes on Wednesday, May 8, 2019. In conjunction with the release, the Company will host a conference call with the investment community that same day at 4:30 p.m. Eastern Time to discuss the financial results and current business developments. A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company's website at ir.axonicsmodulation.com.
- Business Wire
Welkin Health Announces Partnership to Implement an Innovative Program to Support Commercialization of the Axonics® Cutting-Edge Sacral Neuromodulation Therapy
Welkin’s software will streamline workflows for care teams and enable personalized, ongoing support for patients receiving therapy for urinary and fecal dysfunction
- Business Wire
Axonics® Appoints Nancy L. Snyderman, M.D. and Jane E. Kiernan to its Board of Directors
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Nancy L. Snyderman, M.D. and Jane E. Kiernan have been appointed to the Axonics board of directors, effective immediately. Concurrent with this appointment, Shahzad Malik, M.D., general partner with Advent Life Sciences (London), and Geoff Pardo, partner with Gilde Healthcare (Boston), members of the board of directors since 2015 and 2017, respectively, have retired from the Axonics board and will not stand for re-election at the Axonics annual shareholder meeting planned for August 19, 2019.
- Business Wire
Axonics® to Present at the Needham Healthcare Conference
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that members of the management team will present at the 18th Annual Needham Healthcare Conference, Wednesday, April 10, at 10:40 a.m. ET in New York City, and will be available for one-on-one meetings. Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction.
- Business Wire
Axonics® to Participate in Upcoming Investor Events
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM® System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling.
- Business Wire
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. , a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter and year ended December 31, 2018, and provided an update on operational initiatives.
- Business Wire
Axonics® Appoints Michael H. Carrel to its Board of Directors
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Michael H. Carrel has been appointed to the Axonics board of directors, effective immediately. Mr. Carrel has served as the president and CEO and member of the board of AtriCure, Inc. (ATRC) since late 2012.
- Zacks
Ciena (CIEN) to Report Q1 Earnings: A Beat in the Offing?
Ciena's (CIEN) fiscal first-quarter earnings are likely to gain from year-over-year higher revenues resulting from its long-term investments to meet customer needs.
- Business Wire
Axonics® Submits Pivotal Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of pivotal clinical data from the ARTISAN-SNM pivotal clinical study designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1. The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal clinical study approved under an FDA Investigational Device Exemption (“IDE”) to evaluate the safety and efficacy of the Axonics r-SNM System for urinary dysfunction.
- Business Wire
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system.
